GlassScriptPhysician profile
Ashley Lomeli
NPI 1487287611
$4,872.35
in general payments reported to CMS, 2019-2025
27 companies · $21.29 in 2025
The $21.29 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,242 · 2022: $1,513 · 2023: $79.75 · 2024: $16.34 · 2025: $21.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,174.22 | 2021-2022 | |
| Abbvie INC. | $580.04 | 2021-2024 | |
| Lilly USA, LLC | $478.35 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $283.70 | 2021 | |
| Glaxosmithkline, LLC. | $251.92 | 2021-2022 | |
| Amarin Pharma, INC. | $245.82 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.48 | 2021-2022 | |
| Amgen INC. | $195.81 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $178.36 | 2021-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $164.84 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $146.68 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $138.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.78 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.68 | 2021-2022 | |
| Esperion Therapeutics, INC. | $88.24 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.40 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.96 | 2021-2022 | |
| Radius Health, INC. | $59.41 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $53.40 | 2021-2022 | |
| Horizon Therapeutics Plc | $51.30 | 2021 | |
| Genentech USA, INC. | $43.03 | 2021 | |
| Antares Pharma, INC. | $42.38 | 2021-2022 | |
| Neurelis, INC. | $34.88 | 2022 | |
| Corcept Therapeutics | $30.43 | 2022 | |
| Hologic Sales and Service, LLC | $26.14 | 2021 | |
| Ucb, INC. | $24.88 | 2021 | |
| Axsome Therapeutics, INC. | $14.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Lomeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.